Clinical trials
Breast Cancer Recurrent clinical trials
Below are recruiting breast cancer recurrent clinical trials, each written for real people, not researchers. We’re tracking 632 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05942300RecruitingPhase 1
CPI-0209 plus platinum chemo for recurring ovarian cancer
This Phase 1 trial tests CPI-0209 combined with the standard platinum chemotherapy approach in people whose ovarian (or related) cancer has returned after prior platinum treatment. The goal is to find a safe dose and see whether this combination can help keep the cancer under control.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06954480RecruitingPhase 2
Two drugs vs one for PDL1-negative breast cancer
This trial tests a new combination of two drugs (datopotamab deruxtecan plus durvalumab) against one drug alone (datopotamab deruxtecan) for people with PDL1-negative, triple-negative breast cancer that has spread. The goal is to see if the combination works better.
LondonAges 18 years+ - NCT06962163Recruiting
PET scan study for metastatic triple negative breast cancer
This study tests a new PET scan tracer called [68Ga]Ga-PentixaFor to see if it can better detect breast cancer that has spread. You may benefit if you have triple negative breast cancer that has come back or spread, and you are looking for more precise imaging.
Saint-HerblainAges 18 years+ - NCT07111832RecruitingPhase 3
Study of SHR-A1811 for triple-negative breast cancer
This study tests a new drug called SHR-A1811 for people with triple-negative breast cancer that has spread or come back. It looks at whether the drug can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT07558733RecruitingPhase 1/Phase 2
New drug combinations for advanced hormone-receptor positive breast cancer
This trial tests two new drugs (sapanisertib and serabelisib) alone or together to treat advanced breast cancer that is hormone-receptor positive. These drugs target specific pathways that help cancer grow, and the trial will see if they work better than standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT07326800Recruiting
Meditation and values program for breast cancer patients
This trial tests a program called MAEva that combines meditation and acceptance techniques to help patients with non-metastatic breast cancer. It aims to improve well-being by focusing on personal values and coping skills.
Vandœuvre-lès-NancyAges 18 years+ - NCT06470347RecruitingPhase 1/Phase 2
Testing Pyrrolitinib After Trastuzumab for HER2+ Breast Cancer
This study tests if taking pyrrolitinib (a targeted medicine) can further reduce the risk of breast cancer returning in patients with HER2-positive early breast cancer who have already received trastuzumab after surgery.
Zunyi, GuizhouAges 18–75 - NCT04159818RecruitingPhase 2
Adding immune treatments to improve checkpoint drug response in TNBC
This Phase 2 trial tests strategies meant to “prime” the immune system so that immune checkpoint medicines may work better in people with triple-negative breast cancer that has spread (or can’t be fully cured). You might be considered if your cancer has measurable areas that can be biopsied and you meet specific health and prior-treatment rules.
AmsterdamAges 18 years+ - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT06043466RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced solid tumors
This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06638294Recruiting
Study for breast cancer spread to brain lining
This study is for people with breast cancer that has spread to the lining of the brain or spinal cord (called leptomeningeal metastasis). Researchers want to understand how to treat this condition and offer care to those who qualify.
Washington D.C., District of ColumbiaAges 4 months+ - NCT04893109RecruitingPhase 2
Study compares two HER2 breast cancer treatments after surgery
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
San Francisco, CaliforniaAges 18 years+ - NCT04169542Recruiting
Study on how COVID-19 affected costs for breast surgery patients
This study asks people with breast cancer who are having breast surgery about how COVID-19 affected their out-of-pocket costs, work income, and job stability. Your answers may help improve support for patients during public health emergencies.
Conroe, TexasAges 18 years+ - NCT05983107RecruitingPhase 2
Chidamide/Everolimus for advanced breast cancer
This trial tests a combination of two drugs, chidamide and everolimus, for people with advanced HR+/HER2- breast cancer. It aims to see if the combination works for tumors with or without a PIK3CA gene mutation. You may be able to join if you've had previous treatment with CDK4/6 inhibitors and up to two prior chemotherapies.
Beijing, Beijing MunicipalityAges 18–75 - NCT07648914RecruitingPhase 3
BL-B01D1 versus chemotherapy for advanced hormone-receptor-positive breast cancer
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07524114Recruiting
Blood test to find leftover cancer after treatment
This study uses a blood test to look for tiny bits of cancer DNA after you finish treatment. It may help doctors know if cancer is still there and guide next steps.
Toronto, OntarioAges 18 years+ - NCT07424547RecruitingPhase 1
Study of SYS6043 for advanced or metastatic solid tumors
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
Plantation, FloridaAges 18 years+ - NCT05306041RecruitingPhase 2
Pre-surgery hormone therapy with or without PI3K inhibitor
This trial tests whether giving hormone-blocking treatment before surgery works better when combined with an added targeted drug for certain breast cancers. It may help shrink the tumor and improve outcomes for people whose tumors have specific hormone and genetic features.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT06957886RecruitingPhase 3
Study of BL-M07D1 vs chemo for HER2-low breast cancer
This trial tests a new drug, BL-M07D1, against standard chemotherapy for people with HER2-low breast cancer that has spread or come back. It aims to find which treatment works better.
Guangzhou, GuangdongAges 18–75 - NCT06827613RecruitingPhase 1/Phase 2
Study of invikafusp alfa plus sacituzumab govitecan for advanced solid tumors
This trial tests a new drug combination for people with advanced breast cancer (triple-negative or hormone receptor-positive). The goal is to see if the combination helps shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT03730922Recruiting
Delayed vs immediate breast reconstruction after mastectomy and radiation
This study compares two timing options for rebuilding the breast after mastectomy followed by radiation: a reconstruction done later (delayed) versus one done sooner (delayed-immediate). The goal is to see which approach works better and is safer for recovery after treatment.
AabenraaAges 18 years+ - NCT05076682RecruitingPhase 2
Study for hard-to-treat triple-negative breast cancer that keeps growing
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
ShanghaiAges 18–70 - NCT05187832RecruitingPhase 1
Study drug for ER-positive, HER2-negative breast cancer in postmenopausal women
This Phase 1 trial tests AND019, a new study drug, in postmenopausal women with advanced or metastatic ER-positive and HER2-negative breast cancer. It aims to see if the drug is safe and can control the cancer when other standard treatments have stopped working.
Nashville, TennesseeAges 18 years+
Hear when a new Breast Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer recurrent?
- Yes. Clin2 currently lists 632 recruiting breast cancer recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.